Effexor Will Rebound After “Cloud” Over Antidepressant Class Lifts, Wyeth Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Antidepressant growth has stalled amid publicity surrounding pediatric safety data, Wyeth acknowledges. Company still expects Effexor to top $3 bil. this year, helped by strong international sales.